---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Access and coverage questions"
description: "Access and coverage questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cost and coverage and Patient support. Questions: How much does Skyrizi cost with commercial insurance? Is there a Skyrizi savings card? Can Medicare patients use the Skyrizi savings card? What is the Skyrizi Complete patient support program? 6 further questions follow. 10 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Access and coverage questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications](https://www.evicenter.com/medical-information/skyrizi).

## Cost and coverage

<a id="skyrizi-cost-savings-card"></a>

### How much does Skyrizi cost with commercial insurance?

> “90<sup>%</sup>
>
> OF COMMERCIAL CLAIMS FOR A FILLED SKYRIZI PRESCRIPTION COST PATIENTS $0-$5<sup>3§II</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=OF%20COMMERCIAL%20CLAIMS%20FOR%20A,PATIENTS)

> “Based on paid commercial claims data from national data providers for a filled SKYRIZI® (risankizumab-rzaa) prescription for Ps or PsA for the period May 2025 through April 2026, inclusive of savings card redemptions.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=on%20paid%20commercial%20claims%20data,inclusive%20of%20savings%20card%20redemptions.)

> “<sup>§</sup>Patients' actual out-of-pocket costs may vary depending on their insurance coverage and eligibility for support programs.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=actual%20out%2Dof%2Dpocket%20costs%20may%20vary,and%20eligibility%20for%20support%20programs.)

Note: The captured Skyrizi HCP pages state no list price.

<a id="skyrizi-savings-card"></a>

### Is there a Skyrizi savings card?

> “With the Skyrizi Complete Savings Card, your eligible commercially insured patients may pay as little as $0 per quarterly dose. Terms and Conditions of the copay assistance program apply<sup>†</sup>”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=With%20the%20Skyrizi%20Complete%20Savings,of%20the%20copay%20assistance%20program)

> “<sup>†</sup>Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=Available%20to%20patients%20with%20commercial,This%20is%20not%20health%20insurance.)

<a id="skyrizi-savings-card-medicare"></a>

### Can Medicare patients use the Skyrizi savings card?

> “This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law.”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=This%20co%2Dpay%20assistance%20program%20is,or%20where%20prohibited%20by%20law.)

<a id="skyrizi-coverage-denied"></a>

### Can patients get Skyrizi at no cost if insurance denies coverage?

> “Skyrizi Complete may help eligible commercially insured patients experiencing initial coverage denials due to step therapy requirements access their prescribed therapy at no charge while coverage is established or during the appeals process.”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=Skyrizi%20Complete%20may%20help%20eligible,or%20during%20the%20appeals%20process.)

> “No-cost product available for eligible patients in the event of denial in coverage
> due to step-therapy requirement<sup>¶</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=No%2Dcost%20product%20available%20for%20eligible,due%20to%20step%2Dtherapy)

> “<sup>¶</sup>Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=criteria%3A%20Available%20to%20patients%20aged,by%20program.%20Limitations%20may%20apply.)

<a id="skyrizi-insurance-coverage"></a>

### Is Skyrizi covered by commercial insurance and Medicare Part D?

> “SKYRIZI HAS
> ~99% PREFERRED* COMBINED NATIONAL COMMERCIAL AND MEDICARE PART D COVERAGE IN ADULTS WITH Ps & PsA<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=SKYRIZI%20HAS,COVERAGE%20IN%20ADULTS%20WITH%20Ps)

> “National commercial and Medicare Part D formulary coverage under the pharmacy benefit as of April 2026.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=National%20commercial%20and%20Medicare%20Part%20D%20formulary,benefit%20as%20of%20April%202026.)

> “*SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=%2ASKYRIZI%20is%20on%20a%20preferred,status%20on%20the%20plan%E2%80%99s%20formulary.)

> “<sup>†</sup>Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=requirements%20and%20benefit%20designs%20vary,the%20most%20current%20reimbursement%20policies.)

> “PREFERRED COVERAGE MEANS
> SKYRIZI IS AVAILABLE:
>
> With no advanced treatment failure required<sup>‡</sup>
> At the lowest branded co-pay/coinsurance
> tier”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=PREFERRED%20COVERAGE%20MEANS,tier)

> “<sup>‡</sup>Advanced treatments are defined as phosphodiesterase-4 (PDE4) inhibitors, Janus kinase (JAK) inhibitors, or biologics.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=treatments%20are%20defined%20as%20phosphodiesterase%2D4,kinase%20%28JAK%29%20inhibitors%2C%20or%20biologics.)

> “In 2026, annual out-of-pocket costs for all covered Part D drugs will be capped at $2,100.<sup>4</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Access & Coverage for Psoriasis Patients, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/coverage-access#:~:text=In%202026%2C%20annual%20out%2Dof%2Dpocket%20costs,drugs%20will%20be%20capped%20at)

Note: The coverage percentages are AbbVie’s figures for adults with plaque psoriasis and psoriatic arthritis as of April 2026. The Skyrizi Complete Savings Card is not available to patients with Medicare or other government insurance.

<a id="skyrizi-prior-authorization"></a>

### Does Skyrizi need prior authorization?

> “When prescribing SKYRIZI for your patient, determine whether the payer requires a prior authorization (PA). PA 
> requirements may vary by payer, so check with your patient’s health plan for an accurate list of requirements before 
> submitting the request. Ensure that diagnosis, disease severity, prior therapies tried, dosing, duration, and clinical 
> testing are documented to help avoid potential denials due to missing or incomplete information.”

Source: [SKYRIZI: PA BROCHURE, page 2, captured 2026-11-12](https://www.skyrizihcp.com/content/dam/skyrizihcpivy/docs/prior-authorization-instructions-digital.pdf#page=2)

> “Insurance companies have variable Prior 
> Authorization requirements, but most require 
> at least 1 per year.”

Source: [SKYRIZI: dermatology-rheumatology-access-guide.pdf, page 1, captured 2026-11-12](https://www.skyrizihcp.com/content/dam/skyrizihcpivy/docs/dermatology-rheumatology-access-guide.pdf#page=1)

Note: The first passage is from the prior authorization brochure and the second from the guide to starting Skyrizi, both linked from the forms and downloads page of the Skyrizi HCP site.

<a id="skyrizi-prior-authorization-time"></a>

### How long does Skyrizi prior authorization take?

> “If Prior Authorization is approved, the medication 
> will be shipped to the patient. Prior Authorization 
> typically takes between 5 and 10 business days 
> from receipt by the Specialty Pharmacy.”

Source: [SKYRIZI: dermatology-rheumatology-access-guide.pdf, page 1, captured 2026-11-12](https://www.skyrizihcp.com/content/dam/skyrizihcpivy/docs/dermatology-rheumatology-access-guide.pdf#page=1)

Note: The passage is from the guide to starting Skyrizi, linked from the forms and downloads page of the Skyrizi HCP site.

<a id="skyrizi-billing-codes"></a>

### What is the J-code (HCPCS code) for Skyrizi in plaque psoriasis?

> “HCPCS code	Description	Payer type
> J3590	Unclassified biologics	Commercial, Medicare
> C9399	Unclassified drugs or biologics	Medicare”

Source: [SKYRIZI: SKYRIZI® Resources for Patient Access & Support, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support/forms-downloads#:~:text=HCPCS%20code,Medicare)

> “<sup>†</sup>The codes shown above are only general suggestions and are not intended to encourage or suggest a use of any drug that is inconsistent with FDA-approved use.”

Source: [SKYRIZI: SKYRIZI® Resources for Patient Access & Support, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support/forms-downloads#:~:text=codes%20shown%20above%20are%20only,is%20inconsistent%20with%20FDA%2Dapproved%20use.)

> “<sup>‡</sup>This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Providers are encouraged to contact third-party payers for specific information about their coverage policies.”

Source: [SKYRIZI: SKYRIZI® Resources for Patient Access & Support, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support/forms-downloads#:~:text=information%20is%20presented%20for%20informational,information%20about%20their%20coverage%20policies.)

Note: J3590 and C9399 are unclassified codes; the page lists no product-specific HCPCS code for the subcutaneous forms.

<a id="skyrizi-ndc"></a>

### What are the NDC codes for Skyrizi in plaque psoriasis?

> “NDC CODES<sup>1</sup>
>
> SKYRIZI
> Pen 150 mg/mL
>
> 0074-2100-01
> Carton of 1
>
> SKYRIZI Prefilled
> Syringe 150 mg/mL
>
> 0074-1050-01
> Carton of 1
>
> Pediatric
> SKYRIZI Prefilled Syringe 55 mg/0.37 mL
>
> 0074-4059-01
> Carton of 1”

Source: [SKYRIZI: SKYRIZI® Resources for Patient Access & Support, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support/forms-downloads#:~:text=EMAIL-,NDC,Carton%20of%201)

## Patient support

<a id="skyrizi-skyrizi-complete"></a>

### What is the Skyrizi Complete patient support program?

> “Enrolling your patients in Skyrizi Complete will provide your patients the support to start and stay on track with their prescribed treatment, including the resources below.”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=Enrolling%20your%20patients%20in%20Skyrizi,treatment%2C%20including%20the%20resources%20below.)

> “NURSE AMBASSADORS PROVIDE 1:1 SUPPORT TO HELP MEET THE UNIQUE NEEDS OF EACH INDIVIDUAL PATIENT, INCLUDING:
>
> Answering questions throughout the injection experience to help avoid disruptions
> Helping patients make sense of their insurance coverage, helping them find ways to save on prescription costs, and connecting them with additional insurance expertise and resources designed around their prescribed treatment plan
> Providing training to complement the training you have given them, along with supplemental injection training resources
> Helping patients understand their roles in coordinating their treatment (including the delivery of their medication to their doctor’s office in time for their next injection)”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=NURSE%20AMBASSADORS%20PROVIDE%201%3A1%20SUPPORT,time%20for%20their%20next%20injection%29)

> “*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=%2ANurse%20Ambassadors%20are%20provided%20by,treatment%2Drelated%20questions%2C%20including%20further%20referrals.)

> “The Complete App helps patients set reminders, prepare for upcoming doses, and access additional resources.”

Source: [SKYRIZI: SKYRIZI® Complete Savings Card and Patient Support - Dermatology, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/support#:~:text=The%20Complete%20App%20helps%20patients,doses%2C%20and%20access%20additional%20resources.)

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
